SAN DIEGO, Nov. 12 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. , a biopharmaceutical company developing and commercializing products based on the extracellular matrix, today announced that it has been selected for addition to the NASDAQ Biotechnology Index(R) , effective Monday, November 19.
Launched in 1993, the NASDAQ Biotechnology Index is ranked on a semi-annual basis in May and November and serves as the basis for the iShares NASDAQ Biotechnology Fund . Securities included in the NASDAQ Biotechnology Index must be listed on the NASDAQ National Market and be classified according to the FTSE(TM) Global Classification System as either biotechnology or pharmaceutical. Additionally, securities in the index must meet minimum requirements for market value, average daily share volume and seasoning as a public company, among other criteria. For more information about the NASDAQ Biotechnology Index, including eligibility criteria, visit http://www.nasdaq.com.
About Halozyme Therapeutics, Inc.
Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix for the drug delivery, oncology and dermatology markets. The company’s portfolio of products and product candidates is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s Enhanze Technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. Its key partnerships are with Roche to apply Enhanze Technology to Roche’s biological therapeutic compounds for up to 13 targets and with Baxter to apply Enhanze Technology to Baxter’s biological therapeutic compound, GAMMAGARD LIQUID 10%. In addition, the company has received FDA approval for two products: Cumulase(R), for use in in-vitro fertilization, and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. HYLENEX is partnered with Baxter International Inc. The Company also has a number of different enzymes in its portfolio that are targeting significant areas of unmet need.
dramsay@halozyme.com dmarkley@lhai.com
CONTACT: Halozyme, David A. Ramsay, Chief Financial Officer of Halozyme
Therapeutics, Inc., +1-858-704-8260, dramsay@halozyme.com; or Investor
Relations, Don Markley of Lippert-Heilshorn & Associates, +1-310-691-7100,
dmarkley@lhai.com, for Halozyme Therapeutics, Inc.
Web site: http://www.halozyme.com/
